Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > JD really took his lapdogs to the woodshed.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by G1945Von Dec 13, 2022 11:12am
112 Views
Post# 35168466

RE:RE:JD really took his lapdogs to the woodshed.

RE:RE:JD really took his lapdogs to the woodshed.
KayakerBC wrote: Where are the longs? I guess everyone sold awhile ago like JD who still spends so, so much of his tie on this board. Weird and very sad

I'm here.  Have you not done the math?  BTI trading at .18 cents.  MTP at 1.25.

"Deal to be satisfied by issue of 75.9m new shares of 0.1p each in co capital at exchange ratio of 0.9556 shares for each bioasis share"  -- Reuters



So is this it?

 "exchange .9556 Midatech share for each BTI share."

"BTI trading at .18 cents.  MTP at 1.25."


G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities